CPDA-1 1.66 g/63mL (Anticoagulant Citrate Phosphate Dextrose Adenine SOLUTION) 1.66 g/63mL

CPDA-1 1.66 g/63mL is an anticoagulant solution used to preserve blood components. This intravenous solution contains citrate, phosphate, dextrose, and adenine, aiding in blood storage and compatibility.

Strength

1.66 g/63mL

Pack Size

63 mL in 1 BAG (0942-6305-03)

Manufacturer / TM Owner

Fenwal, Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

CPDA-1 1.66 g/63mL is primarily used to prevent blood clotting during storage. This solution is designed to maintain the quality and viability of blood components, such as red blood cells, for transfusion purposes. It is commonly used in medical settings where blood preservation is necessary.

Side Effects

The primary effect of CPDA-1 1.66 g/63mL is to inhibit clotting by binding calcium ions. This solution also provides nutrients to support cellular metabolism, helping to extend the shelf life of stored blood. Users may notice the solution's clear appearance and its role in maintaining blood component integrity.

Precautions & Warnings

CPDA-1 1.66 g/63mL should be handled with care to avoid contamination. It is important to follow proper storage guidelines and use sterile techniques when administering this solution. Always check the solution for any signs of damage or discoloration before use.

Avoid Interactions

CPDA-1 1.66 g/63mL may interact with certain medications or substances that affect blood clotting. It is advisable to consult with a healthcare provider before using this solution alongside other treatments. Additionally, avoid mixing with incompatible solutions to prevent adverse reactions.

Frequently Asked Questions

CPDA-1 1.66 g/63mL is used to preserve blood components by preventing clotting and providing essential nutrients.

CPDA-1 1.66 g/63mL should be stored according to the manufacturer's guidelines, typically in a cool, dry place away from direct sunlight.

The main components of CPDA-1 1.66 g/63mL include citrate, phosphate, dextrose, and adenine, which work together to preserve blood.

It is important to consult with a healthcare provider before using CPDA-1 1.66 g/63mL with other medications to avoid potential interactions.

If you notice any discoloration or signs of damage in the CPDA-1 1.66 g/63mL solution, do not use it and consult a healthcare professional.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 28 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.